Crossmark

Initial treatment with a single capsule containing half-dose quadruple therapy versus standard-dose dual therapy in hypertensive patients (QUADUAL): statistical analysis plan for a randomized, blinded, crossover trial

Crossref DOI link: https://doi.org/10.1186/s13063-023-07803-1

Published Online: 2024-01-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Xiexiong

Li, Xingli

Liu, Tao

Yang, Guoping

Chen, Ye

Huang, Miao

Zhao, Lin

Li, Xiaogang

Jiang, Weihong http://orcid.org/0000-0001-8369-9694
Funding

Funding for this research was provided by:

Key Research and Development Program of Hunan Province of China (2022SK2029)

National Natural Science Foundation of China (81800271)
License Information

Text and Data Mining valid from 2024-01-13

Version of Record valid from 2024-01-13
More Information

Article History

Received: 30 July 2023

Accepted: 13 November 2023

First Online: 13 January 2024

Declarations

:

: The study has been approved by the Institutional Review Board of the Third Xiangya Hospital of Central South University (R22023). All patients can voluntarily participate in and withdraw from the study. The purpose and method of the study will be informed in detail and the informed consent will be obtained. All investigators ensure the confidentiality of patient data.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below